Page last updated: 2024-12-11
6-selenoguanine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
6-selenoguanine: analog of 6-thioguanine with superior therapeutic index & lower toxicity; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6337487 |
| CHEMBL ID | 295864 |
| SCHEMBL ID | 157322 |
| MeSH ID | M0053743 |
Synonyms (8)
| Synonym |
|---|
| 2-amino-1,7-dihydro-6h-purine-6-selone |
| 6-selenoguanine |
| CHEMBL295864 |
| 5375-85-9 |
| SCHEMBL157322 |
| AYLMUGUFZHMFIK-UHFFFAOYSA-N |
| DTXSID00968515 |
| (2-imino-3,9-dihydro-2h-purin-6-yl)selanyl |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (11)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID98781 | Median survival time at a compound dose of 100 mg/kg, in mice bearing L1210 cells on days 1 and 5 | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| AID98289 | Ratio of the median survival time (treated(T) versus control(C)) at a dose of 50 mg/kg, on days 1 and 5 | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| AID233530 | The number of mice survived to that of total when no compound dose was given on 30th day | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| AID98793 | Median survival time at a compound dose of 50 mg/kg, in mice bearing L1210 cells on days 1 and 5 | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| AID96816 | In vitro inhibitory concentration required for 50% inhibition of L1210 cell growth | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| AID230171 | The number of mice survived to that of total at a dose of 100 mg/kg on 30th day; 3/5 | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| AID97793 | Effect dose of 50 mg/kg on day 3, before L1210 cell transplantation in mice | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| AID98278 | Ratio of the median survival time (treated(T) versus control(C)) at a dose of 100 mg/kg, on days 1 and 5 | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| AID98787 | Median survival time at a compound dose of 200x2 mg/kgxdays, in mice bearing L1210 cells on days 1 and 5; Toxic | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| AID230182 | The number of mice survived to that of total at a dose of 50 mg/kg on 30th day; 1/5 | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| AID98799 | Median survival time when no dose was administered in mice bearing L1210 cells on days 1 and 5 | 1981 | Journal of medicinal chemistry, Feb, Volume: 24, Issue:2 | Synthesis of seleno- and thioguanine-platinum(II) complexes and their antitumor activity in mice. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||